Endovascular Today
The 2024 PAD Guideline Update: How It Affects Practice. The most significant changes from the previous guidelines, achieving buy-in and consensus, key trends, obstacles to achieving appropriate care, ensuring compliance with medical therapy and exercise, and effective communication and the multidisciplinary care team.
Gore’s Excluder TAMBE Approved by FDA to Treat Complex Aortic …
January 25, 2024—Gore & Associates announced FDA approval for the Excluder thoracoabdominal branch endoprosthesis (TAMBE). The device is an off-the-shelf endovascular solution for the treatment of complex aneurysmal disease involving the visceral aorta.
Biotronik’s BIO-OSCAR FIRST Trial Begins Enrollment
December 19, 2024—Biotronik announced the enrollment of the first patients in its BIO-OSCAR FIRST trial, which is designed to confirm the safety and clinical performance of the company’s Oscar peripheral multifunctional catheter for dilation of lesions in the femoral, popliteal, and infrapopliteal arteries, including both above-the-knee (ATK) and below-the-knee (BTK) lesions.
Merit Medical’s Wrapsody Receives FDA Approval
December 20, 2024—Merit Medical Systems, Inc. announced that the Wrapsody cell-impermeable endoprosthesis has received premarket approval from the FDA.
US Device Guide - Endovascular Today
Download our Device Guide App. The Device Guide app, brought to you by Endovascular Today and Cardiac Interventions Today, provides a comprehensive listing of vascular and coronary interventional devices available in both the United States and CE Mark markets.This easy-to-use format places all four editions of our Guides (US and European) into one central tool.
December 2024 Supplement - Endovascular Today
December 2024 Supplement. Peripheral Arterial Clot? #POUNCEIT. When minutes matter – remove acute or chronic thrombi or emboli without aspiration, thrombolytics, or capital equipment.
Humacyte’s Symvess ATEV Approved by FDA for Treatment of …
December 19, 2024—Humacyte, Inc. announced that the FDA has granted full approval for the company’s Symvess—acellular tissue engineered vessel-tyod (ATEV)—for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and when autologous vein graft is not feasible.
Fluid Biomed Closes Financing for Studies of ReSolv Stent in Brain ...
December 16, 2024—Fluid Biomed Inc. announced it closed a $27 million Series A equity financing round. The funds will be used to advance clinical investigations of the company’s bioabsorbable polymer-based ReSolv stent technology to treat brain aneurysms.
Synchron’s Brain-Computer Interface Evaluated in COMMAND …
October 3, 2024—Synchron recently announced positive results from the COMMAND early feasibility study, which is evaluating the safety and efficacy of the Synchron brain computer interface (BCI, called the Stentrode) in six patients over a 12-month period.. The results were presented by the COMMAND study Coprincipal Investigator Elad Levy, MD, at the 2024 Congress of Neurological Surgeons ...
Contego’s Neuroguard IEP System Used in First Commercial …
December 19, 2024—Contego Medical announced the first commercial procedures were performed with the company’s Neuroguard IEP system. According to Contego, Neuroguard IEP is a three-in-one device combining a high-performance carotid stent, an integrated dilation balloon, and an integrated filter.